Roche Adds Non-Invasive Prenatal Testing to Pipeline with Ariosa Acquisition
Roche announced the acquisition of Ariosa Diagnostics, a molecular diagnostics testing service provider and maker of the prenatal blood test, Harmony.
Roche announced on Dec. 2, 2014 the acquisition of Ariosa Diagnostics, a US-based molecular diagnostics company providing highly-targeted, non-invasive prenatal testing (NIPT) using cell-free DNA (cfDNA) technology. The transaction is expected to close in December 2014.
Ariosa’s blood test, Harmony Prenatal Test, evaluates fetal cfDNA found in maternal blood and is designed to assess the risk of genetic abnormalities, including Down syndrome. The test specifically analyzes trisomies 13, 18, and 21 and has a false-positive result of less than 0.1%.
“Circulating cfDNA has the promise of providing early diagnostic information through a simple blood test in many important segments including pregnancy, cancer, and transplantation, aligning with our strategy in personalized healthcare and commitment to setting new standards of care,” said Roland Diggelmann, COO Roche Diagnostics Division, in a press release.
Source: Roche
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
